Namaste Technologies (CSE:N; OTCMKTS:NXTTF) announced a non-binding letter of intent to acquire 15 percent of the share capital from Pineapple Express with the right to get an additional 10 percent.

As quoted in the press release:


Namaste Technologies is pleased to announce that it has signed a non-binding letter of intent (“LOI”) with Pineapple Express Delivery Inc. (“Pineapple Express”), whereby Namaste will invest $1,000,000 to acquire 15% of the share capital of Pineapple Express and obtain a right of first refusal to purchase an additional 10% of the share capital for an additional $1,200,000.

Pineapple Express currently operates a same-day delivery service for medical cannabis and expects to expand across Canada. Pineapple Express’ management team have a proven track record of launching cross-country same-day delivery services, having sold a previous same-day delivery venture to Just Eat Canada.

The proposed agreement will allow Namaste and Pineapple Express to expand on Pineapple Express’ existing same-day delivery service for medical cannabis platform to provide same-day delivery of medical cannabis across Canada. Namaste intends to assist with the development and marketing of Pineapple Express’ brand and in the optimization of its existing software platform. Namaste will also look to leverage its international exposure and offer Pineapple Express’ fully-integrated software application to international cannabis licensed producers.

Click here to read the full press release.

Source: globenewswire.com

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less